Northern Trust Corp Has $110,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Northern Trust Corp boosted its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 29.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 64,737 shares of the company’s stock after acquiring an additional 14,572 shares during the quarter. Northern Trust Corp owned approximately 0.16% of Vigil Neuroscience worth $110,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in VIGL. Blair William & Co. IL bought a new stake in Vigil Neuroscience during the 4th quarter worth about $551,000. Renaissance Technologies LLC grew its holdings in Vigil Neuroscience by 698.5% during the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company’s stock worth $624,000 after acquiring an additional 321,300 shares during the last quarter. abrdn plc grew its holdings in Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company’s stock worth $898,000 after acquiring an additional 293,461 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Vigil Neuroscience during the 4th quarter worth about $249,000. Finally, Marshall Wace LLP grew its holdings in Vigil Neuroscience by 85.3% during the 4th quarter. Marshall Wace LLP now owns 266,895 shares of the company’s stock worth $454,000 after acquiring an additional 122,853 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

VIGL has been the topic of a number of research analyst reports. Stifel Nicolaus lowered shares of Vigil Neuroscience from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $11.00 to $8.00 in a report on Wednesday, May 28th. Citizens Jmp lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 22nd. Citigroup lowered shares of Vigil Neuroscience to a “market perform” rating in a research note on Thursday, May 22nd. JMP Securities reaffirmed a “market perform” rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Finally, Mizuho lowered shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Ten analysts have rated the stock with a hold rating, According to MarketBeat, Vigil Neuroscience presently has an average rating of “Hold” and a consensus target price of $10.80.

Vigil Neuroscience Trading Down 0.3%

Shares of NASDAQ VIGL opened at $7.91 on Wednesday. The firm has a market capitalization of $369.18 million, a PE ratio of -3.84 and a beta of 1.90. The firm’s 50-day moving average is $3.04 and its 200-day moving average is $2.51. Vigil Neuroscience, Inc. has a 1 year low of $1.31 and a 1 year high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. As a group, equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current fiscal year.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.